Journal
BIOFACTORS
Volume 49, Issue 2, Pages 351-364Publisher
WILEY
DOI: 10.1002/biof.1925
Keywords
Myocardium; cardiac troponins; cardiomyocytes; tissue necrosis; healthy subjects; athletes; cardiac necrosis
Ask authors/readers for more resources
Cardiac troponins are key elements in the regulation of cardiac excitation-contraction coupling and can be used as biomarkers of acute myocardial infarction. With the use of high sensitivity immunoassay tests, they can also be used as biomarkers for other cardiac conditions. This review discusses the mechanisms of cardiac troponin release in the blood and its potential as a biomarker for cardiac adverse events.
The cardiac troponins (cTns), cardiac troponin C (cTnC), cTnT, and cTnI are key elements of myocardial apparatus, fixed as protein complex on the thin filament of sarcomere and are involved in the regulation of excitation-contraction coupling of cardiomyocytes in the presence of Ca2+. Circulating cTnT and cTnI (cTns) increase following cardiac tissue necrosis, and they are consolidated biomarkers of acute myocardial infarction (AMI). However, the use of high sensitivity (hs)-immunoassay tests for cTnT and cTnI has made it possible to identify a multitude of other clinical conditions associated with increased circulating levels of cTns. cTns can be measured also in the peripheral circulation of healthy subjects or athletes, suggesting that different mechanisms are involved in the release of cTns in the blood independently of cardiac cell necrosis. In this review, the molecular/cellular mechanisms involved in cTns release in blood and the exploitation of cTnI and cTnT as biomarkers of cardiac adverse events, in addition to cardiac necrosis, are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available